Clinical trial
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia
NCT00077467 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077467 |
|---|---|
| Title | Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia |
| Official title | A Phase I Study of PS-341 (Velcade, Bortezomib) in Pediatric Patients With Refractory/Recurrent Leukemias |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia |
| Intervention type | Drug, Other |
| Interventions | bortezomib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 36 |
| Start date | Jan 1, 2004 |
| Primary completion | Mar 1, 2006 |
| First posted | Feb 12, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: